Track Record – Acidophil

Acidophil co-founded AgriMetis in 2014 with a Series A financing of $10M
Focused on innovating sustainable crop protection products through leading edge discovery, development and delivery methods.
AgriMetis raised $23.5M Series B capital in 2017.

Acidophil co-founded Chalante in 2017 with additional grant support from Innovate UK.
Focused on the development of parasiticides for food and companion animals that address unmet needs in animal health.

Corridor Pharmaceuticals was formed by the merger of Arginetix Pharma (founded by Acidophil in 2007) and Immune Control to develop arginase inhibitor based therapeutics for respiratory and cardiac indications.
Raised $2 million seed funds from Acidophil, MedImmune Ventures and Quaker BioVentures and Red Abbey Venture Partners, then attracted a $7 million Series A financing.
Acquired by AstraZeneca.

PGT developed tools, that contribute to a better understanding of the inherent complexity of human, animal, plant and microbiological genomes.
PGT was formed following a £1 million seed investment from Wellcome Trust, and then raised £3.5 million Series A from Auriga, Beringea and Compass Genetics (which includes Acidophil), before raising a further £5 million Series B from Syngenta Ventures and Series A investors.
PGT with Acidophil’s help is in the process of commercializing its technologies by licensing out intellectual property and sales to research tool and molecular diagnostic companies.

Cost-competitive solutions to produce renewable intermediate chemicals via a bio-based or a fully biological approach using any one of a number of specifically tailored microorganisms that can utilise low cost feedstocks.
Zuvasyntha was founded by the merger of Biosyntha and Zuvachem